国际皮肤性病学杂志
國際皮膚性病學雜誌
국제피부성병학잡지
International Journal of Dermatology and Venereology
2015年
6期
360-362
,共3页
皮肤纤维肉瘤%外科手术%Mohs外科手术%放射治疗剂量%分子靶向治疗
皮膚纖維肉瘤%外科手術%Mohs外科手術%放射治療劑量%分子靶嚮治療
피부섬유육류%외과수술%Mohs외과수술%방사치료제량%분자파향치료
Dermatofibrosarcoma%Surgical procedures,operative%Mohs surgery%Radiotherapy dosage%Molecular targeted therapy
隆突性皮肤纤维肉瘤是一种罕见的交界恶性/潜在低度恶性肿瘤,局部复发率高,远处转移率低.隆突性皮肤纤维肉瘤好发年龄20 ~ 50岁,好发部位为躯干,典型临床表现为在萎缩性斑块基础上出现直径大小不一的多发硬性结节,组织学特征由单一编席样或车辐状排列的梭形细胞组成,呈浸润性生长.隆突性皮肤纤维肉瘤的标准治疗方式是局部扩大切除,外科切缘通常要求为2~3cm.Mohs手术以及改良Mohs手术有良好的治疗前景,术后可适当辅以放射治疗.近年来,隆突性皮肤纤维肉瘤发病机制得到进一步阐明,90%的隆突性皮肤纤维肉瘤患者发生染色体17和22重排,靶向药物方面已批准伊马替尼可用于治疗不能切除和(或)转移和(或)复发性隆突性皮肤纤维肉瘤患者.
隆突性皮膚纖維肉瘤是一種罕見的交界噁性/潛在低度噁性腫瘤,跼部複髮率高,遠處轉移率低.隆突性皮膚纖維肉瘤好髮年齡20 ~ 50歲,好髮部位為軀榦,典型臨床錶現為在萎縮性斑塊基礎上齣現直徑大小不一的多髮硬性結節,組織學特徵由單一編席樣或車輻狀排列的梭形細胞組成,呈浸潤性生長.隆突性皮膚纖維肉瘤的標準治療方式是跼部擴大切除,外科切緣通常要求為2~3cm.Mohs手術以及改良Mohs手術有良好的治療前景,術後可適噹輔以放射治療.近年來,隆突性皮膚纖維肉瘤髮病機製得到進一步闡明,90%的隆突性皮膚纖維肉瘤患者髮生染色體17和22重排,靶嚮藥物方麵已批準伊馬替尼可用于治療不能切除和(或)轉移和(或)複髮性隆突性皮膚纖維肉瘤患者.
륭돌성피부섬유육류시일충한견적교계악성/잠재저도악성종류,국부복발솔고,원처전이솔저.륭돌성피부섬유육류호발년령20 ~ 50세,호발부위위구간,전형림상표현위재위축성반괴기출상출현직경대소불일적다발경성결절,조직학특정유단일편석양혹차복상배렬적사형세포조성,정침윤성생장.륭돌성피부섬유육류적표준치료방식시국부확대절제,외과절연통상요구위2~3cm.Mohs수술이급개량Mohs수술유량호적치료전경,술후가괄당보이방사치료.근년래,륭돌성피부섬유육류발병궤제득도진일보천명,90%적륭돌성피부섬유육류환자발생염색체17화22중배,파향약물방면이비준이마체니가용우치료불능절제화(혹)전이화(혹)복발성륭돌성피부섬유육류환자.
Dermatofibrosarcoma protuberans (DFSP) is a rare borderline malignant or potentially low-grade malignant neoplasm with a high local recurrence rate and a low risk of metastasis.DFSP usually occurs on the trunk in people aged 20-50 years,and is characterized by multiple indurated nodules varying in size and arising on atrophic plaques.Histologically,the tumor consists of uniform spindle cells which grow infiltratively and are arranged in a storiform or cartwheel pattern.The standard therapy of DFSP is wide local excision with a margin of 2-3 cm.Mohs' surgery and modified Mohs' surgery have shown a good prospect in the treatment of DFSP.Radiation therapy can serve as an adjuvant treatment after surgery.In recent years,the pathogenesis of DFSP has been further clarified and studies have shown that chromosomes 17 and 22 are rearranged in 90% of patients with DFSP.As a targeted drug,imatinib has been approved for the treatment of DFSP in patients with unresectable,metastatic and/or recurrent DFSP.